A cross-border Goodwin team advised Abingworth on its proposed acquisition by global investment firm Carlyle (NASDAQ: CG). The transaction, once completed, will combine Abingworth’s established track record in investing across early- and late-stage biotech companies with Carlye’s leading global healthcare franchise.
Abingworth is a leading transatlantic life sciences investment firm with over $2 billion under management. The company is a longstanding client of Goodwin, drawing on the firm’s focus on the intersection of capital and innovation, and its particular strengths in private investment funds, life sciences, and healthcare. Last year, Goodwin advised Abingworth on its successful fundraising for Abingworth Bioventures 8 and Abingworth Clinical Co-Development Fund 2, which together raised over $1 billion in new funds to invest in life sciences companies developing innovative therapeutics with potential to significantly improve human health.
Carlyle is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Global Investment Solutions.
The Goodwin team was led by Tom LaFond, Ajay Pathak, Ravi Chopra, and included Kimberly Rodriguez and Marc Tetreault on corporate aspects, Karen Turk, Katie Leah, Laura Charkin, Sonita Bennitt and Rebecca Wallis on tax, Brynn Peltz and Glynn Barwick on regulatory matters, Koray Bulut and Nina Ngo on employment, James Mattus on benefits, and Simone Waterbury and Kevin Walsh on antitrust matters.
For more details on the acquisition, please read the press release.